NextPoint Therapeutics, Inc.
NextPoint Therapeutics, Inc.
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm | Recruiting | Phase 1 | 2026-09-08 | NCT07563829 | |
| A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm | Recruiting | Phase 1 | 2025-06-27 | NCT06240728 |